Analyst Conference Call Notes by William Meyers

Biotechnology Investor Aids

Celsion
CLSN

conference date: November 15, 2019 @ 8:00 AM Pacific Time

Celsion Interim Thermodox Analysis Recommends Continuation of Study [November 4, 2019]

Celsion Approaches Drug Trial Binary [May 19, 2019]

Independent NIH Analysis of Thermodox plus RFA for Liver Cancer [September 12, 2016]

RFA plus lyso-thermosensitive liposomal doxorubicin [June 10, 2016] all the details on Thermodox studies

2019
Celsion
Q1 2019
call notes
Celsion
Q2 2019
call notes
Celsion
Q3 2019
call notes
 
May 15, 2019 Aug. 15, 2019 Nov. 15, 2019  
2018
Celsion
Q4 2018
call notes
May 10, 2018
Aug. 14, 2018
Nov. 15, 2018
Mar. 29, 2019
2017
May 12, 2017
August 15, 2017
Nov. 14, 2017
March 27, 2018
2016
 
08/15/2016
11/10/2016
03/16/2017
 

Celsion (CLSN) is a clinical-stage biotechnology company specializing in cancer therapies. Its lead product is ThermoDox for liver cancer.

Celsion web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 MYL
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2019 William P. Meyers